Reuters logo
BRIEF-Phase 3 study with filgotinib initiated in crohn's disease
2016年11月22日 / 晚上9点12分 / 1 年前

BRIEF-Phase 3 study with filgotinib initiated in crohn's disease

Nov 22 (Reuters) - Galapagos Nv

* Phase 3 study with filgotinib initiated in crohn’s disease

* Galapagos NV says start of diversity study triggers a $50 million milestone payment from Gilead Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below